UTMB:1022 PATENT

ABSTRACT

[0104] The present invention includes the selection and isolation of thioaptamers that target the signaling protein TGF- β 1, compositions of such thioaptamers and the use of such thioaptamers to either block or enhance signal transduction of the TGF- β 1 protein and thus function as, e.g., immunomodulatory agents. Thioaptamers may also be targeted alone or in combination with other thioaptamers against the ligand, the receptors, the ligand trap protein(s) and/or the coreceptors to modulate TGF- β signaling pathway.

5